tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

QuidelOrtho Completes Major Debt Refinancing Transaction

Story Highlights
  • QuidelOrtho completed a debt refinancing with a Credit Agreement on August 21, 2025.
  • The refinancing extends debt maturities and enhances financial flexibility for future growth.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
QuidelOrtho Completes Major Debt Refinancing Transaction

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

QuidelOrtho ( (QDEL) ) just unveiled an update.

On August 21, 2025, QuidelOrtho Corporation completed a significant debt refinancing transaction, entering into a Credit Agreement with Bank of America and other lenders. This agreement includes a $1.15 billion senior secured term loan A, a $100 million delayed draw term loan A, a $1.45 billion senior secured term loan B, and a $700 million revolving credit facility. The refinancing allows QuidelOrtho to extend its debt maturities, reduce required amortization payments, and improve financial flexibility, supporting future growth and strengthening its capital structure.

The most recent analyst rating on (QDEL) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.

Spark’s Take on QDEL Stock

According to Spark, TipRanks’ AI Analyst, QDEL is a Neutral.

QuidelOrtho’s overall stock score is primarily influenced by its financial performance and earnings call insights. While the company shows potential for recovery with improved debt management and cash flow, recent losses and a negative P/E ratio weigh heavily on its valuation. The technical analysis suggests a bearish trend, further impacting the score. Positive earnings call highlights, such as growth in key segments and improved profitability metrics, provide some optimism but are counterbalanced by revenue declines in North America and COVID segments.

To see Spark’s full report on QDEL stock, click here.

More about QuidelOrtho

QuidelOrtho Corporation is a global leader in in vitro diagnostics, offering innovative diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine. The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing fast, accurate, and reliable diagnostics from home to hospital, lab to clinic.

Average Trading Volume: 1,456,878

Technical Sentiment Signal: Sell

Current Market Cap: $1.82B

For a thorough assessment of QDEL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1